Jennifer
Gjerde
Post doctor
Visit Address:
Haukeland universitetssykehus, Laboratoriebygget
5021 Bergen
Postal Address:
Postboks 7804
5021 Bergen
Phone:
+47 55 97 43 98
E-mail:
Journal articles
- 2014. Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults. Lipids in Health and Disease. 13:82. doi: 10.1186/1476-511X-13-82
- 2013. Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. Experimental and clinical endocrinology & diabetes. 121. 1 pages. doi: 10.1055/s-0033-1336763
- 2013. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 141: 243-248. doi: 10.1007/s10549-013-2677-9
- 2013. Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements. Obesity. 21: 2495-2503. doi: 10.1002/oby.20449
- 2013. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research. 15. 11 pages. doi: 10.1186/bcr3439
- 2013. Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncologica. 52: 861-U216. doi: 10.3109/0284186X.2012.742963
- 2012. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Research and Treatment. 134: 693-700. doi: 10.1007/s10549-012-2074-9
- 2012. Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 12. 12 pages. doi: 10.1186/1471-2407-12-247
- 2012. The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss. International Journal of Obesity. 36: 1195-1202. doi: 10.1038/ijo.2011.240
- 2011. Functional polymorphisms in UDP-glucuronosyltransferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiology, Biomarkers and Prevention. 20: 1937-1943. Published 2011-07-12. doi: 10.1158/1055-9965.EPI-11-0419
- 2011. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. The Pharmacogenomics Journal. 11: 100-107. doi: 10.1038/tpj.2010.17
- 2010. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 10. 13 pages. doi: 10.1186/1471-2407-10-313
- 2010. Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 8: 60-60.
- 2010. Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clinical Cancer Research. 16: 2176-2186. doi: 10.1158/1078-0432.CCR-09-1859
- 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 109: 592-592.
- 2008. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 19: 56-61. doi: 10.1093/annonc/mdm434
- 2008. Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of Bone and Mineral Research. 23: 1267-1277. doi: 10.1359/JBMR.080319
- 2007. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. Journal of Clinical Oncology. 25: 4201-4209. doi: 10.1200/JCO.2006.09.4318
- 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. S106.
- 2007. Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. 16: S15-S15.
- 2007. A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. 106: S144-S144. Published 2007-10-24. doi: 10.1007/s10549-007-9793-3
- 2006. Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 98: 231-234. doi: Se sammendrag
- 2005. Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. 94: S236-S237.
- 2005. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A. 1082: 6-14. doi: 10.1016/j.chroma.2005.01.004
- 2005. Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. Journal of Steroid Biochemistry and Molecular Biology. 94: 489-498. doi: 10.1016/j.jsbmb.2004.12.037
- 2004. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial. Clinical Cancer Research. 10: 2336-2343.
- 2003. Tamoxifen administration and metabolism in nude mice and nude rats. Journal of Steroid Biochemistry and Molecular Biology. 84: 361-367.
Reports and theses
- 2008. Tamoxifen treatment of breast cancer: Pharmacogenetics and therapeutic drug monitoring. 119 pages.
Book sections
- 2011. Steroid Receptor Coactivators and Endocrine Treatment in Breast Cancer. 2, pages 35-66. In:
- 2011. Nuclear Receptors. Nova Science Publishers, Inc.. 174 pages. ISBN: 978-1-61209-980-4.
- 2011. Steroid Receptor Coactivators and Their Expression, Regulation and Functional Role in Endocrine Responsive and Resistant Breast Cancer. 35, pages 715-732. In:
- 2011. Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways. INTECH. 732 pages. ISBN: 978-953-307-714-7.
More information in national current research information system (CRIStin)